सेलेकॉक्सिब और वेनलाफैक्सिन का इंटरैक्शन

Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet drugs (e.g., aspirin), SSRIs and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk.

Intervention: Monitor patients with concomitant use of VYSCOXA with anticoagulants (e.g., warfarin), antiplatelet drugs (e.g., aspirin), SSRIs, and SNRIs for signs of bleeding [ see Warnings and Precautions (5.12) ].

• Drugs that Interfere with Hemostasis (e.g., warfarin, aspirin, selective serotonin reuptake inhibitors [SSRIs]/serotonin norepinephrine reuptake inhibitors [SNRIs]) : Monitor patients for bleeding who are concomitantly taking VYSCOXA with drugs that interfere with hemostasis.

Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk.

Patients should be cautioned about the increased risk of bleeding associated with the concomitant use of Venlafaxine Extended Release Tablets and NSAIDs, aspirin, or other drugs that affect coagulation.

These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.

Drugs that Interfere with Hemostasis (e.g., NSAID’s, Aspirin, and Warfarin) Serotonin release by platelets plays an important role in hemostasis.